763 studies found for:    trastuzumab
Show Display Options
Rank Status Study
21 Recruiting Breast Cancer Treatment Using Weekly Carboplatin + Paclitaxel With Pertuzumab + Trastuzumab (HER2+) or Bevacizumab (HER2-) in the Neoadjuvant Setting
Condition: Breast Carcinoma
Interventions: Drug: Carboplatin;   Drug: Paclitaxel;   Drug: Bevacizumab;   Drug: Trastuzumab;   Drug: Pertuzumab
22 Active, not recruiting
Has Results
Combination Chemotherapy and Paclitaxel Plus Trastuzumab in Treating Women With Palpable Breast Cancer That Can Be Removed by Surgery
Conditions: HER2/Neu Positive;   Stage IA Breast Cancer;   Stage IB Breast Cancer;   Stage II Breast Cancer;   Stage IIIA Breast Cancer
Interventions: Drug: Cyclophosphamide;   Drug: Epirubicin Hydrochloride;   Other: Laboratory Biomarker Analysis;   Drug: Paclitaxel;   Procedure: Therapeutic Conventional Surgery;   Biological: Trastuzumab
23 Recruiting Trial of Neoadjuvant Trastuzumab Emtansine in Patients With HER2-Equivocal Breast Cancer
Condition: Breast Cancer
Intervention: Drug: Trastuzumab emtansine
24 Terminated Combination Chemotherapy, Surgery, and Radiation Therapy With or Without Dexrazoxane and Trastuzumab in Treating Women With Stage III or Stage IV Breast Cancer
Conditions: Cardiac Toxicity;   Inflammatory Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIB Breast Cancer;   Stage IV Breast Cancer
Interventions: Drug: dexrazoxane hydrochloride;   Drug: doxorubicin hydrochloride;   Drug: cyclophosphamide;   Drug: paclitaxel;   Biological: trastuzumab;   Procedure: therapeutic conventional surgery;   Radiation: radiation therapy;   Drug: tamoxifen citrate;   Other: laboratory biomarker analysis
25 Active, not recruiting Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer
Conditions: Estrogen Receptor Negative;   Estrogen Receptor Positive;   HER2/Neu Positive;   Progesterone Receptor Negative;   Progesterone Receptor Positive;   Recurrent Breast Carcinoma;   Stage IA Breast Cancer;   Stage IB Breast Cancer;   Stage IIA Breast Cancer;   Stage IIB Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIC Breast Cancer
Interventions: Drug: Cyclophosphamide;   Drug: Docetaxel;   Drug: Doxorubicin Hydrochloride;   Other: Laboratory Biomarker Analysis;   Drug: Paclitaxel;   Other: Quality-of-Life Assessment;   Biological: Trastuzumab
26 Completed PET Imaging With Cu-64 Labeled Trastuzumab in HER2+ Metastatic Breast Cancer
Condition: Breast Cancer
Intervention: Radiation: PET Imaging With Cu-64 Labeled Trastuzumab
27 Recruiting Intrathecal Trastuzumab Administration in Metastatic Breast Cancer Patients Developing Carcinomatous Meningitis
Conditions: Metastatic Breast Cancer;   Carcinomatous Meningitis
Intervention: Drug: Trastuzumab
28 Completed A Phase Ib/II Study of BEZ235 and Trastuzumab in Patients With HER2-positive Breast Cancer Who Failed Prior to Trastuzumab
Conditions: Locally Advance Breast Cancer (LABC);   Metastatic Breast Cancer (MBC)
Interventions: Drug: BEZ235 + Trastuzumab Phase l/Phase ll);   Drug: Lapatinib + Capecitabine (Phase II)
29 Terminated Trastuzumab in Treating Patients With Metastatic or Recurrent Salivary Gland Cancer
Conditions: High-grade Salivary Gland Mucoepidermoid Carcinoma;   Recurrent Salivary Gland Cancer;   Salivary Gland Acinic Cell Tumor;   Salivary Gland Adenocarcinoma;   Salivary Gland Poorly Differentiated Carcinoma;   Stage IVA Salivary Gland Cancer;   Stage IVB Salivary Gland Cancer;   Stage IVC Salivary Gland Cancer
Interventions: Biological: trastuzumab;   Other: laboratory biomarker analysis
30 Completed
Has Results
A Study of Trastuzumab-Mcc-DM1 Administered Intravenously to Patients With HER2-Positive Metastatic Breast Cancer
Condition: Metastatic Breast Cancer
Intervention: Drug: Trastuzumab emtansine [Kadcyla]
31 Active, not recruiting Neoadjuvant Carboplatin, Weekly Abraxane and Trastuzumab in HER2+ Breast Cancer
Condition: Breast Cancer
Interventions: Drug: Carboplatin;   Drug: nab-paclitaxel;   Drug: trastuzumab
32 Recruiting Safety and QoL of Trastuzumab With Lapatinib or Chemiotherapy in MBC and HER2+ Patients Refractory to Anti HER2 Therapies
Condition: Metastatic Breast Cancer
Interventions: Drug: Lapatinib;   Drug: Trastuzumab
33 Active, not recruiting Doxorubicin Hydrochloride, Cyclophosphamide, and Pacltaxel With or Without Trastuzumab in Treating Women With HER2-Positive Node-Positive or High-Risk Node-Negative Breast Cancer
Conditions: Breast Adenocarcinoma;   HER2 Positive Breast Carcinoma;   Stage IA Breast Cancer;   Stage IB Breast Cancer;   Stage IIA Breast Cancer;   Stage IIB Breast Cancer;   Stage IIIA Breast Cancer
Interventions: Drug: Aromatase Inhibition Therapy;   Drug: Cyclophosphamide;   Drug: Doxorubicin Hydrochloride;   Other: Laboratory Biomarker Analysis;   Drug: Paclitaxel;   Drug: Tamoxifen Citrate;   Biological: Trastuzumab
34 Active, not recruiting Neoadjuvant 5-fluorouracil, Epirubicin and Cyclophosphamide (FEC) Followed by Weekly Paclitaxel and Trastuzumab in Her2 Positive Breast Cancer
Condition: HER-2 Positive Breast Cancer
Intervention: Drug: Trastuzumab
35 Active, not recruiting A Study to Compare the Safety and Efficacy of an Aromatase Inhibitor in Combination With Lapatinib, Trastuzumab or Both for the Treatment of Hormone Receptor Positive, HER2+ Metastatic Breast Cancer
Condition: Neoplasms, Breast
Interventions: Drug: lapatinib;   Drug: trastuzumab;   Drug: Aromatase inhibitor
36 Recruiting Trastuzumab Combined With Chemotherapy or Endocrine Therapy to Treat Metastatic Luminal B2 Breast Cancer
Condition: Breast Cancer
Interventions: Drug: Endocrine therapy combined with trastuzumab;   Drug: Chemotherapy combined with trastuzumab
37 Recruiting Ado-Trastuzumab Emtansine in Treating Patients With HER2-Positive Metastatic or Locally Advanced Breast Cancer That Cannot Be Removed by Surgery
Conditions: HER2/Neu Positive;   Recurrent Breast Carcinoma;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer;   Stage IV Breast Cancer
Interventions: Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study;   Biological: Trastuzumab Emtansine
38 Unknown  Efficacy of Combination of Trastuzumab to Gemcitabine - Platinum Advanced or Metastatic Urothelial Carcinoma
Conditions: Recurrent Bladder Cancer;   Stage IV Bladder Cancer;   Transitional Cell Carcinoma of the Bladder
Interventions: Biological: Trastuzumab;   Drug: Gemcitabine;   Drug: Carboplatin;   Drug: Cisplatin
39 Recruiting Everolimus, Letrozole and Trastuzumab in HR- and HER2/Neu-positive Patients
Conditions: Breast Cancer;   Solid Tumors
Interventions: Drug: Everolimus;   Drug: Trastuzumab;   Drug: Letrozole
40 Terminated Akt Inhibitor MK2206, Lapatinib Ditosylate, and Trastuzumab in Treating Patients With Locally Advanced or Metastatic HER2-Positive Breast , Gastric, or Gastroesophageal Cancer That Cannot Be Removed By Surgery
Conditions: Adenocarcinoma of the Gastroesophageal Junction;   HER2-positive Breast Cancer;   Male Breast Cancer;   Recurrent Breast Cancer;   Recurrent Esophageal Cancer;   Recurrent Gastric Cancer;   Stage IIIC Breast Cancer;   Stage IIIC Esophageal Cancer;   Stage IIIC Gastric Cancer;   Stage IV Breast Cancer;   Stage IV Esophageal Cancer;   Stage IV Gastric Cancer
Interventions: Drug: Akt inhibitor MK2206;   Biological: trastuzumab;   Drug: lapatinib ditosylate;   Other: laboratory biomarker analysis

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Indicates status has not been verified in more than two years